SPY302.97-0.56 -0.18%
DIA254.35-1.42 -0.56%
IXIC9,368.99-43.37 -0.46%

B. Riley FBR Upgrades CymaBay Therapeutics to Buy, Raises Price Target of $6

B. Riley FBR upgrades CymaBay Therapeutics (NASDAQ:CBAY) from Neutral to Buy and raises the price target from $1.5 to $6.

Benzinga · 05/13/2020 10:52

B. Riley FBR upgrades CymaBay Therapeutics (NASDAQ:CBAY) from Neutral to Buy and raises the price target from $1.5 to $6.